Synthetic control arms and generative AI in clinical trials

Synthetic control arms (SCAs) and generative AI are making some serious waves in clinical trials, and for good reason. They offer exciting possibilities to make trials more efficient, ethical, and ultimately, faster at getting new treatments to patients. Essentially, an SCA uses existing real-world data or simulated data to create a ‘control group’ digitally, rather than recruiting actual patients for a placebo or standard-of-care arm. Generative AI, meanwhile, helps build and refine these SCAs, and can even design entirely new data sets to test hypotheses. It’s a pretty powerful combination that’s changing how we think about clinical research.

The traditional clinical trial model, with its reliance on large control groups, has served us well, but it also has its drawbacks. This is where SCAs come in as a practical solution.

Ethical Considerations and Patient Recruitment

One of the biggest hurdles in clinical trials is patient recruitment, especially for rare diseases. Imagine a condition affecting only a few thousand people worldwide. Asking some of those precious few to receive a placebo, knowing they have a potentially life-threatening illness, presents a significant ethical dilemma. SCAs offer an alternative, allowing more patients to receive the experimental treatment.

Minimising Placebo Exposure: For conditions with high unmet needs or severe symptoms, reducing the number of patients on placebo is a huge ethical win.
Rare Disease Trials: In rare disease populations, every patient counts. SCAs can significantly reduce the sample size needed for the control arm, making trials more feasible.
Paediatric Trials: Similar to rare diseases, getting children to participate in trials, especially if it means receiving a placebo, is incredibly challenging. SCAs can offer a more ethical and practical path forward.

Efficiency and Cost Savings

Running a clinical trial is a complex, time-consuming, and expensive endeavour. SCAs can streamline many aspects, leading to notable improvements in efficiency and reduced costs.

Faster Trial Timelines: Recruiting and monitoring a traditional control group takes time. By using an SCA, parts of the trial can be sped up, potentially bringing therapies to market quicker.
Reduced Operational Costs: Less patient recruitment, fewer site visits, and reduced drug supply for the control arm all contribute to significant cost savings.
Smaller Sample Sizes: While not always the case, SCAs can sometimes lead to smaller overall trial populations, which further reduces costs and logistical complexities.

Overcoming Data Limitations

Sometimes, a traditional control group simply isn’t practical or even possible. Think about historical data or situations where a new treatment is so promising that withholding it from a control group would be unethical.

Historical Controls: SCAs can leverage historical patient data, provided it’s robust and comparable, to build a control group without needing to recruit new patients.
Adaptive Trial Designs: SCAs can be integrated into adaptive trial designs, allowing for more flexible and efficient adjustments as the trial progresses.
“Orphan Drug” Development: For treatments targeting very small patient populations, SCAs can be a game-changer, making drug development economically viable where it might not have been otherwise.

Generative AI: The Powerhouse Behind SCAs

Generative AI isn’t just a buzzword; it’s the engine that’s making sophisticated SCAs a reality. Its ability to learn from and create new data is revolutionary for clinical research.

Crafting Realistic Synthetic Data

One of the core applications of generative AI in this space is creating synthetic data that closely mimics real-world patient data. This is crucial for building robust and reliable SCAs.

Data Imputation and Augmentation: AI can fill in missing data points in existing datasets or even generate new, realistic patient profiles to expand the size and diversity of an SCA.
Maintaining Data Fidelity: Advanced generative models can ensure that the synthetic data maintains the statistical properties, correlations, and nuances present in the original real-world data, making it highly representative.
De-identification for Privacy: Generative AI can create synthetic datasets that are statistically similar to real patient data but contain no identifiable patient information, addressing critical privacy concerns.

Identifying and Matching Control Patients

Finding the right historical or real-world patients to form a comparable control group is a complex task. Generative AI excels at this.

Advanced Matching Algorithms: AI can analyse vast amounts of patient data to identify individuals who closely match the characteristics of the experimental treatment group, ensuring a valid comparison.
Propensity Score Matching: Generative AI can refine propensity score matching techniques, which account for baseline differences between groups, leading to more accurate comparisons.
Personalised Control Profiles: AI can even create ‘personalised’ synthetic control profiles that match individual patients in the experimental arm, offering a higher level of precision.

Simulating Trial Outcomes

Beyond just creating data, generative AI can simulate how patients might respond to treatments, offering valuable insights before and during a trial.

Predicting Placebo Response: AI can be trained on historical placebo response rates to create a more accurate prediction of what a control group’s outcome might be.
Scenario Planning: Researchers can use AI to simulate different trial scenarios, such as varying patient demographics or treatment dosages, to optimise trial design.
Identifying Subgroup Responses: Generative AI can help identify potential subgroups within a patient population that might respond differently to treatment, informing future research.

Challenges and Considerations for Adoption

While the potential of SCAs and generative AI is immense, it’s not a straightforward path. There are significant challenges that need careful consideration for successful adoption.

Data Quality and Availability

The old adage “garbage in, garbage out” has never been more relevant than with AI. The success of SCAs hinges on high-quality, readily available data.

Heterogeneity of Real-World Data: Real-world data comes from various sources (electronic health records, registries, claims data) and can be inconsistent in format, completeness, and quality.
Bias in Historical Data: Historical datasets might reflect past medical practices, diagnostic criteria, or demographic biases that could skew SCA results if not carefully accounted for.
Data Curation and Standardisation: A significant effort is required to standardise and curate real-world data to make it suitable for generative AI models and SCA construction.

Regulatory Acceptance and Trust

Regulators are understandably cautious when it comes to new methodologies that could impact patient safety and treatment efficacy. Building trust is paramount.

Validation Methodologies: Clear, robust methodologies for validating the statistical equivalence and predictive accuracy of SCAs are needed to satisfy regulatory bodies.
Transparency and Explainability: The “black box” nature of some AI models can be a barrier. Regulators will require transparency in how SCAs are constructed and how generative AI models arrive at their conclusions.
Guidance and Frameworks: Regulatory agencies need to develop clear guidelines and frameworks for the use of SCAs and AI in clinical trials, providing a roadmap for developers.

Ethical and Privacy Concerns

Even with de-identification techniques, the use of patient data, whether real or synthetic, raises important ethical and privacy questions.

Data Security: Protecting sensitive patient data, even when anonymised or de-identified, is a critical ongoing concern.
Informed Consent: While SCAs reduce the need for new control patients, the ethical considerations around the original data used for the SCA still need careful thought.
Bias Amplification: If the training data for generative AI contains inherent biases (e.g., underrepresentation of certain ethnic groups), the AI could inadvertently amplify these biases in the SCA, leading to inequitable outcomes.

The Future Landscape: Integration and Innovation

The trajectory for SCAs and generative AI in clinical trials points towards deeper integration and continuous innovation. This isn’t just a fleeting trend; it’s a fundamental shift.

Hybrid Trial Designs

We’re likely to see a move towards ‘hybrid’ trial designs that combine elements of traditional trials with SCAs. This offers a pragmatic stepping stone.

Partial Synthetic Controls: A trial might use a smaller traditional control arm supplemented by a larger synthetic control arm, offering a balance between ethical considerations and statistical robustness.
Adaptive SCA Integration: As more data becomes available during a trial, the SCA could be continuously updated and refined, making the control arm more dynamic and accurate.
“Living” SCAs: Imagine SCAs that continuously learn from new real-world data as it emerges, providing an ever-evolving and highly relevant comparison group.

Advanced AI Models and Techniques

The field of generative AI is moving at an incredible pace, and new models and techniques will undoubtedly enhance the capabilities of SCAs.

Foundation Models for Healthcare Data: Large language models and other foundation models, tailored for complex healthcare data, could revolutionise how we generate and interpret synthetic control data.
Causal Inference with AI: AI’s ability to model causality, rather than just correlation, will be crucial for building more robust SCAs that can truly isolate the treatment effect.
Explainable AI (XAI): Further advancements in XAI will help demystify the decisions made by generative AI models, fostering greater trust and regulatory acceptance.

Redefining Evidence Generation

Ultimately, the widespread adoption of SCAs and generative AI could fundamentally change how we generate evidence for new treatments, making the process more dynamic and patient-centric.

Continuous Evidence Generation: Instead of discrete trial phases, we might see a more continuous process of evidence generation, where treatments are constantly being evaluated against real-world and synthetic controls.
Personalised Medicine Integration: SCAs and AI can pave the way for more personalised treatment evaluations, where the effectiveness of a drug is assessed against a control group tailored to an individual patient’s profile.
Accelerated Drug Development: By reducing the time and cost of clinical trials, these technologies have the potential to significantly accelerate the development and approval of life-saving medicines.

In conclusion, synthetic control arms, powered by generative AI, aren’t just a niche application; they represent a significant leap forward in clinical research. While challenges remain, the ethical, efficiency, and data-driven benefits are too compelling to ignore. As technology matures and regulatory frameworks adapt, we’re set to see these tools play an increasingly central role in bringing innovative treatments to those who need them most.